What is the company's stated purpose for rolling out its leading global brand 
ally invest in building up this leading brand.
What we're doing is that we have a stated purpose to make a global commercial reach and meaning is that we first place we roll out is in the US. Then we have Europe, and then we have China, we have Japan and then you can take the rest of the world. So from that perspective is that we also believe in a global price structure, global -- globalization much, much, much more. So from our perspective is that we integrate all this. And this is only a small step what we do initially. But what we basic are building up a model that basic are saying, how can we build out the leading global brand specific in US if you only talk about that, a leading brand in the US and create most value. So we will optimize it in the best possible way. And never starting to be saying is that we need to force ourself in this fast rollout. We will be sure that the value of TransCon growth hormone will basic take in and sell you more and more patients with more and more physicians that see the real value we provide to TransCon growth hormone.
Jesper, specific for US, will you further comments on it?
Jesper Hoiland -- Senior Vice President, Global Chief Commercial Officer
Yeah, absolutely. I mean, we are having a superior product. And, of course, we would like that to see reflected in the price that we are going to approach the market with. So just to keep that in mind, we will address the commercial market in the first place as that is the biggest business opportunity for us. And as far as we see things, it is the value that is the market leadership that we will be fighting for. So if you're saying we will not take each and every account into consideration in terms of giving it the broadest possible availability, we will certainly go for the value opportunity that we're certainly seeing with the -- we want to take so much of in.
Jan Moller Mikkelsen -- President and Chief Executive Officer
I think this is a great way to answer it, Jesper. It actually describe what we would do with each of our pipeline product opportunities.
David Lebovitz -- Morgan Stanley -- Analyst
Thank you for taking my question.
Operator
Thank you. Our next question comes from the line of Alethia Young with Cantor Fitzgerald. Your line is now open.
Alethia Young -- Cantor Fitzgerald -- Analyst
Hey guys, thanks for taking my question, and looking forward to the next month. I guess I just wanted to talk a little bit about on the growth hormone side, kind of some of the socioeconomic -- kind of economic claims and kind of benefits to having your product versus others and how you think about balancing that as you think the price of the drug. Thanks.
Jan Moller Mikkelsen -- President and Chief Executive Officer
So mainly the pharmacoeconomic calculation we have done is basic not looking on different brands, but mainly focused on the benefit on being on a growth hormone treatment compared to not having the growth hormone treatment available or potential stopping earlier in a growth hormone treatment because of the high burden of a daily injection. And I think this is where we basic have done most of our claim analysis. When you compare different brands, I actually think that you should for me at least when I'm looking from thinking about the patient, the physician and payer, you need to look at what you're providing of integrated benefit related to endocrine health because this is where the social economic calculation kicks in because it's not only height, this is the entire way to having the right way to do remodeling on the body, meaning growth hormone so much will be need to distribute everywhere in the body.
Cognitive effect, which are impossible to measure in children but we know growth hormone have cognitive impact because there's also a lot of growth hormone receptor in the brain. All that is the part of why we believe it was so important for us that everyone could understand our mode of action is building on what we know that growth hormone daily treatment can give because we have the same active ingredients out there. And I think t
ally invest in building up this leading brand.
What we're doing is that we have a stated purpose to make a global commercial reach and meaning is that we first place we roll out is in the US. Then we have Europe, and then we have China, we have Japan and then you can take the rest of the world. So from that perspective is that we also believe in a global price structure, global -- globalization much, much, much more. So from our perspective is that we integrate all this. And this is only a small step what we do initially. But what we basic are building up a model that basic are saying, how can we build out the leading global brand specific in US if you only talk about that, a leading brand in the US and create most value. So we will optimize it in the best possible way. And never starting to be saying is that we need to force ourself in this fast rollout. We will be sure that the value of TransCon growth hormone will basic take in and sell you more and more patients with more and more physicians that see the real value we provide to TransCon growth hormone.
Jesper, specific for US, will you further comments on it?
Jesper Hoiland -- Senior Vice President, Global Chief Commercial Officer
Yeah, absolutely. I mean, we are having a superior product. And, of course, we would like that to see reflected in the price that we are going to approach the market with. So just to keep that in mind, we will address the commercial market in the first place as that is the biggest business opportunity for us. And as far as we see things, it is the value that is the market leadership that we will be fighting for. So if you're saying we will not take each and every account into consideration in terms of giving it the broadest possible availability, we will certainly go for the value opportunity that we're certainly seeing with the -- we want to take so much of in.
Jan Moller Mikkelsen -- President and Chief Executive Officer
I think this is a great way to answer it, Jesper. It actually describe what we would do with each of our pipeline product opportunities.
David Lebovitz -- Morgan Stanley -- Analyst
Thank you for taking my question.
Operator
Thank you. Our next question comes from the line of Alethia Young with Cantor Fitzgerald. Your line is now open.
Alethia Young -- Cantor Fitzgerald -- Analyst
 Hey guys, thanks for taking my question, and looking forward to the next month. I guess I just wanted to talk a little bit about on the growth hormone side, kind of some of the socioeconomic -- kind of economic claims and kind of benefits to having your product versus others and how you think about balancing that as you think the price of the drug. Thanks.
Jan Moller Mikkelsen -- President and Chief Executive Officer
So mainly the pharmacoeconomic calculation we have done is basic not looking on different brands, but mainly focused on the benefit on being on a growth hormone treatment compared to not having the growth hormone treatment available or potential stopping earlier in a growth hormone treatment because of the high burden of a daily injection. And I think this is where we basic have done most of our claim analysis. When you compare different brands, I actually think that you should for me at least when I'm looking from thinking about the patient, the physician and payer, you need to look at what you're providing of integrated benefit related to endocrine health because this is where the social economic calculation kicks in because it's not only height, this is the entire way to having the right way to do remodeling on the body, meaning growth hormone so much will be need to distribute everywhere in the body.
Cognitive effect, which are impossible to measure in children but we know growth hormone have cognitive impact because there's also a lot of growth hormone receptor in the brain. All that is the part of why we believe it was so important for us that everyone could understand our mode of action is building on what we know that growth hormone daily treatment can give because we have the same active ingredients out there. And I think t